Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7840, USA.
Expert Rev Anticancer Ther. 2010 Jan;10(1):103-14. doi: 10.1586/era.09.168.
Since its approval by the US FDA in 1986, prostate-specific antigen (PSA) has been employed to monitor men with a diagnosis of prostate cancer. In 1994, PSA was approved for use in prostate cancer screening and has been employed worldwide. However, due to the limited specificity of PSA for the disease, novel biomarkers are needed for detecting prostate cancer and for determining which cancers need to be treated. This review will discuss the development of new biomarkers for prostate cancer detection and disease prognostication, focusing on recent progress and particular topical issues related to the development and validation of these new markers.
自 1986 年被美国食品和药物管理局（FDA）批准以来，前列腺特异性抗原（PSA）一直被用于监测被诊断患有前列腺癌的男性。1994 年，PSA 获准用于前列腺癌筛查，并在全球范围内得到应用。然而，由于 PSA 对该疾病的特异性有限，因此需要新型生物标志物来检测前列腺癌，并确定需要治疗的癌症。本文将讨论用于前列腺癌检测和疾病预后判断的新型生物标志物的开发，重点介绍这些新型标志物的开发和验证方面的最新进展和特定热门问题。
